{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:00Z","timestamp":1787009400238,"version":"build-2736575974"},"reference-count":97,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:p>Background. It remains unclear which phosphate binders should be preferred for hyperphosphatemia management in chronic kidney disease (CKD).<\/jats:p>\n                  <jats:p>Methods. We performed a systematic review and meta-analysis of randomized trials comparing sevelamer or lanthanum with other phosphate binders in CKD.<\/jats:p>\n                  <jats:p>Results. Fifty-one trials (8829 patients) were reviewed. Compared with calcium-based binders, all-cause mortality was nonsignificantly lower with sevelamer {risk ratio [RR] 0.62 [95% confidence interval (CI) 0.35\u20131.08]} and lanthanum [RR 0.73 (95% CI 0.18\u20133.00)], but risk of bias was concerning. Compared with calcium-based binders, sevelamer reduced the risk of hypercalcemia [RR 0.27 (95% CI 0.17\u20130.42)], as did lanthanum [RR 0.12 (95% CI 0.05\u20130.32)]. Sevelamer reduced hospitalizations [RR 0.50 (95% CI 0.31\u20130.81)], but not lanthanum [RR 0.80 (95% CI 0.34\u20131.93)]. The presence\/absence of other clinically relevant outcomes was infrequently reported. Compared with calcium-based binders, sevelamer reduced serum calcium, low-density lipoprotein and coronary artery calcification, but increased intact parathyroid hormone. The clinical relevance of these changes is unknown since corresponding clinical outcomes were not reported. Lanthanum had less favorable impact on biochemical parameters. Sevelamer hydrochloride and sevelamer carbonate were similar in three studies. Sevelamer was similar to lanthanum (three studies) and iron-based binders (three studies).<\/jats:p>\n                  <jats:p>Conclusion. Sevelamer was associated with a nonsignificant reduction in mortality and significantly lower hospitalization rates and hypercalcemia compared with calcium-based binders. However, differences in important outcomes, such as cardiac events, fractures, calciphylaxis, hyperchloremic acidosis and health-related quality of life remain understudied. Lanthanum and iron-based binders did not show superiority for any clinically relevant outcomes. Future studies that fail to measure clinically important outcomes (the reason why phosphate binders are prescribed in the first place) will be wasteful.<\/jats:p>","DOI":"10.1093\/ndt\/gfw312","type":"journal-article","created":{"date-parts":[[2016,9,20]],"date-time":"2016-09-20T20:59:01Z","timestamp":1474405141000},"page":"111-125","source":"Crossref","is-referenced-by-count":28,"title":["The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"32","author":[{"given":"Steven","family":"Habbous","sequence":"first","affiliation":[{"name":"1Department of Epidemiology & Biostatistics, Western University, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Przech","sequence":"additional","affiliation":[{"name":"1Department of Epidemiology & Biostatistics, Western University, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rey","family":"Acedillo","sequence":"additional","affiliation":[{"name":"1Department of Epidemiology & Biostatistics, Western University, London, ON, Canada"},{"name":"2London Health Sciences Centre, Division of Nephrology, Western University, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisira","family":"Sarma","sequence":"additional","affiliation":[{"name":"1Department of Epidemiology & Biostatistics, Western University, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit X.","family":"Garg","sequence":"additional","affiliation":[{"name":"1Department of Epidemiology & Biostatistics, Western University, London, ON, Canada"},{"name":"2London Health Sciences Centre, Division of Nephrology, Western University, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Martin","sequence":"additional","affiliation":[{"name":"1Department of Epidemiology & Biostatistics, Western University, London, ON, Canada"},{"name":"3Centre for Medical Evidence, Decision Integrity & Clinical Impact (MEDICI), Department of Anesthesia & Perioperative Medicine, Western University, Room B3-412, 339 Windermere Road, London, ON N6A 5A5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,9,20]]},"reference":[{"key":"2025102312490806300_gfw312-B1","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2215\/CJN.06550613","article-title":"Prevalence, awareness, and management of CKD and cardiovascular risk factors in publicly funded health care","volume":"9","author":"Verhave","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312490806300_gfw312-B2","doi-asserted-by":"crossref","first-page":"e004251","DOI":"10.1136\/bmjopen-2013-004251","article-title":"Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study","volume":"4","author":"Neovius","year":"2014","journal-title":"BMJ Open"},{"key":"2025102312490806300_gfw312-B3","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2005101085","article-title":"Chronic kidney disease and mortality risk: a systematic review","volume":"17","author":"Tonelli","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2025102312490806300_gfw312-B4","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1053\/j.ajkd.2004.07.022","article-title":"Coronary artery calcification in patients with CRF not undergoing dialysis","volume":"44","author":"Russo","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2025102312490806300_gfw312-B5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00774-014-0639-x","article-title":"Chronic kidney disease and bone metabolism","volume":"33","author":"Kazama","year":"2015","journal-title":"J Bone Miner Metab"},{"key":"2025102312490806300_gfw312-B6","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1681\/ASN.2006070771","article-title":"Metabolic bone disease in chronic kidney disease","volume":"18","author":"Martin","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2025102312490806300_gfw312-B7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/TP.0000000000000903","article-title":"The kidney-vascular-bone axis in the chronic kidney disease-mineral bone disorder","volume":"100","author":"Seifert","year":"2016","journal-title":"Transplantation"},{"key":"2025102312490806300_gfw312-B8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1517\/14740338.2014.907791","article-title":"Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles","volume":"13","author":"Locatelli","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"2025102312490806300_gfw312-B9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/kisup.2012.66","article-title":"Chapter 3: Management of progression and complications of CKD","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2025102312490806300_gfw312-B10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1744-9987.2007.00432.x","article-title":"Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage","volume":"11","author":"Oka","year":"2007","journal-title":"Ther Apher Dial"},{"key":"2025102312490806300_gfw312-B11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40620-016-0266-9","article-title":"Phosphate binders in chronic kidney disease: a systematic review of recent data","volume":"29","author":"Floege","year":"2016","journal-title":"J Nephrol"},{"key":"2025102312490806300_gfw312-B12","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/ndt\/gfm561","article-title":"Sevelamer: a promising but unproven drug","volume":"22","author":"Palmer","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312490806300_gfw312-B13","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis","volume":"382","author":"Jamal","year":"2013","journal-title":"Lancet"},{"key":"2025102312490806300_gfw312-B14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2215\/CJN.06800615","article-title":"Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials","volume":"11","author":"Patel","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312490806300_gfw312-B15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11255-014-0876-x","article-title":"Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"47","author":"Zhai","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"2025102312490806300_gfw312-B16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.ajkd.2009.06.004","article-title":"Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials","volume":"54","author":"Navaneethan","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2025102312490806300_gfw312-B17","doi-asserted-by":"crossref","first-page":"c259","DOI":"10.1159\/000313484","article-title":"Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients","volume":"115","author":"Zhang","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"2025102312490806300_gfw312-B18","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","article-title":"Long-term effects of iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients","volume":"30","author":"Floege","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312490806300_gfw312-B19","author":"Higgins","year":"2011"},{"key":"2025102312490806300_gfw312-B20","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","article-title":"Calculating the number needed to treat for trials where the outcome is time to an event","volume":"319","author":"Altman","year":"1999","journal-title":"BMJ"},{"key":"2025102312490806300_gfw312-B21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2288-9-21","article-title":"Calculation of NNTs in RCTs with time-to-event outcomes: a literature review","volume":"9","author":"Hildebrandt","year":"2009","journal-title":"BMC Med Res Methodol"},{"key":"2025102312490806300_gfw312-B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-7-5","article-title":"Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data","volume":"7","author":"Friedrich","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"2025102312490806300_gfw312-B23","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/sim.6383","article-title":"Statistical methods for meta-analyses including information from studies without any events-add nothing to nothing and succeed nevertheless","volume":"34","author":"Kuss","year":"2015","journal-title":"Stat Med"},{"key":"2025102312490806300_gfw312-B24","doi-asserted-by":"crossref","first-page":"h1435","DOI":"10.1136\/bmj.h1435","article-title":"Meta-analyses: what is heterogeneity?","volume":"350","author":"Sedgwick","year":"2015","journal-title":"BMJ"},{"key":"2025102312490806300_gfw312-B25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5414\/CNP62104","article-title":"Long-term comparison of a calcium-free phosphate binder and calcium carbonate\u2014phosphorus metabolism and cardiovascular calcification","volume":"62","author":"Braun","year":"2004","journal-title":"Clin Nephrol"},{"key":"2025102312490806300_gfw312-B26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1755-6686.2013.12009.x","article-title":"Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis","volume":"39","author":"Chennasamudram","year":"2013","journal-title":"J Ren Care"},{"issue":"(Suppl 9)","key":"2025102312490806300_gfw312-B27","first-page":"S108","article-title":"Sevelamer worsens metabolic acidosis in hemodialysis patients","volume":"19","author":"De Santo","year":"2006","journal-title":"J Nephrol"},{"key":"2025102312490806300_gfw312-B28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.03820411","article-title":"Mortality in kidney disease patients treated with phosphate binders: a randomized study","volume":"7","author":"Di Iorio","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312490806300_gfw312-B29","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.ajkd.2013.03.023","article-title":"Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial","volume":"62","author":"Di Iorio","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2025102312490806300_gfw312-B30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1681\/ASN.2006101089","article-title":"Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients","volume":"19","author":"Ferreira","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2025102312490806300_gfw312-B31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.ajkd.2010.10.055","article-title":"Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients","volume":"57","author":"Kakuta","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2025102312490806300_gfw312-B32","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/nep.12319","article-title":"Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients","volume":"19","author":"Lin","year":"2014","journal-title":"Nephrology (Carlton)"},{"key":"2025102312490806300_gfw312-B33","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ndt\/18.3.582","article-title":"Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study","volume":"18","author":"Sadek","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312490806300_gfw312-B34","first-page":"785","article-title":"Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients","volume":"25","author":"Shaheen","year":"2004","journal-title":"Saudi Med J"},{"key":"2025102312490806300_gfw312-B35","doi-asserted-by":"crossref","first-page":"934","DOI":"10.2215\/CJN.12891211","article-title":"Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease","volume":"7","author":"Vlassara","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312490806300_gfw312-B36","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/sj.ki.5002518","article-title":"The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer","volume":"72","author":"Russo","year":"2007","journal-title":"Kidney Int"},{"key":"2025102312490806300_gfw312-B37","first-page":"466","article-title":"Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients","volume":"27","author":"Caravaca","year":"2007","journal-title":"Nefrologia"},{"key":"2025102312490806300_gfw312-B38","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1744-9987.2005.00294.x","article-title":"Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan","volume":"9","author":"Koiwa","year":"2005","journal-title":"Ther Apher Dial"},{"key":"2025102312490806300_gfw312-B39","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0272-6386(99)70221-0","article-title":"A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients","volume":"33","author":"Bleyer","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"2025102312490806300_gfw312-B40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2215\/CJN.02810707","article-title":"Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients","volume":"3","author":"Caglar","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312490806300_gfw312-B41","doi-asserted-by":"crossref","first-page":"c273","DOI":"10.1159\/000170783","article-title":"Phosphate binder impact on bone remodeling and coronary calcification\u2014results from the BRiC study","volume":"110","author":"Barreto","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"2025102312490806300_gfw312-B42","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/ndt\/gfn488","article-title":"Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis","volume":"24","author":"Evenepoel","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312490806300_gfw312-B43","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1046\/j.1523-1755.63.s85.17.x","article-title":"Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate","volume":"85","author":"Herv\u00e1s","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"2025102312490806300_gfw312-B44","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0929-6646(10)60107-6","article-title":"Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients","volume":"109","author":"Lin","year":"2010","journal-title":"J Formos Med Assoc"},{"key":"2025102312490806300_gfw312-B45","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","article-title":"Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?","volume":"5","author":"Oliveira","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312490806300_gfw312-B46","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","article-title":"A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study","volume":"51","author":"Qunibi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2025102312490806300_gfw312-B47","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1523-1755.2004.00590.x","article-title":"Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study)","volume":"65","author":"Qunibi","year":"2004","journal-title":"Kidney Int"},{"key":"2025102312490806300_gfw312-B48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","article-title":"Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial","volume":"59","author":"Yilmaz","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2025102312490806300_gfw312-B49","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2025102312490806300_gfw312-B50","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1093\/ndt\/gfq292","article-title":"Evaluation of calcium acetate\/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability","volume":"25","author":"de Francisco","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312490806300_gfw312-B51","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis","volume":"68","author":"Block","year":"2005","journal-title":"Kidney Int"},{"key":"2025102312490806300_gfw312-B52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"key":"2025102312490806300_gfw312-B53","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"key":"2025102312490806300_gfw312-B54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1744-9987.2012.01071.x","article-title":"Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis","volume":"16","author":"Kasai","year":"2012","journal-title":"Ther Apher Dial"},{"key":"2025102312490806300_gfw312-B55","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5414\/CNP72252","article-title":"Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study","volume":"72","author":"Sprague","year":"2009","journal-title":"Clin Nephrol"},{"key":"2025102312490806300_gfw312-B56","first-page":"9","article-title":"The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients","volume":"64","author":"Zwiech","year":"2011","journal-title":"Wiad Lek"},{"key":"2025102312490806300_gfw312-B57","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4103\/0971-4065.98754","article-title":"Sevelamer carbonate experience in Indian end stage renal disease patients","volume":"22","author":"Abraham","year":"2012","journal-title":"Indian J Nephrol"},{"key":"2025102312490806300_gfw312-B58","doi-asserted-by":"crossref","first-page":"386","DOI":"10.5414\/CNP68386","article-title":"A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis","volume":"68","author":"Delmez","year":"2007","journal-title":"Clin Nephrol"},{"key":"2025102312490806300_gfw312-B59","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1093\/ndt\/gfp372","article-title":"A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis","volume":"24","author":"Fan","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312490806300_gfw312-B60","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1046\/j.1523-1755.63.s85.18.x","article-title":"A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients","volume":"85","author":"D'Haese","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"2025102312490806300_gfw312-B61","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/ndt\/gfl146","article-title":"Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up","volume":"21","author":"Spasovski","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312490806300_gfw312-B62","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5414\/CNP70404","article-title":"Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia","volume":"70","author":"Shigematsu","year":"2008","journal-title":"Clin Nephrol"},{"key":"2025102312490806300_gfw312-B63","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/1744-9987.12153","article-title":"Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial","volume":"18","author":"Wada","year":"2014","journal-title":"Ther Apher Dial"},{"key":"2025102312490806300_gfw312-B64","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/1074248413486355","article-title":"Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study","volume":"18","author":"Ohtake","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2025102312490806300_gfw312-B65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5414\/CN107764","article-title":"The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients","volume":"80","author":"Soriano","year":"2013","journal-title":"Clin Nephrol"},{"key":"2025102312490806300_gfw312-B66","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1440-1797.2010.01412.x","article-title":"Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial","volume":"16","author":"Toussaint","year":"2011","journal-title":"Nephrology (Carlton)"},{"key":"2025102312490806300_gfw312-B67","doi-asserted-by":"crossref","first-page":"c8","DOI":"10.1159\/000084653","article-title":"Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate","volume":"100","author":"Hutchison","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"2025102312490806300_gfw312-B68","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5414\/CN107362","article-title":"Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study","volume":"79","author":"Lee","year":"2013","journal-title":"Clin Nephrol"},{"key":"2025102312490806300_gfw312-B69","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5414\/CN107257","article-title":"Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study","volume":"78","author":"Toida","year":"2012","journal-title":"Clin Nephrol"},{"key":"2025102312490806300_gfw312-B70","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4103\/0253-7613.56074","article-title":"Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease","volume":"41","author":"Scaria","year":"2009","journal-title":"Indian J Pharmacol"},{"key":"2025102312490806300_gfw312-B71","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/08860220600925388","article-title":"A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients","volume":"28","author":"Liu","year":"2006","journal-title":"Ren Fail"},{"key":"2025102312490806300_gfw312-B72","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2215\/CJN.01650211","article-title":"Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients","volume":"6","author":"Navarro-Gonzalez","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312490806300_gfw312-B73","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1440-1797.2011.01509.x","article-title":"Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: a 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride","volume":"16","author":"Chen","year":"2011","journal-title":"Nephrology (Carlton)"},{"key":"2025102312490806300_gfw312-B74","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"key":"2025102312490806300_gfw312-B75","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/ndt\/gft483","article-title":"A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis","volume":"29","author":"Yokoyama","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312490806300_gfw312-B76","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1093\/ndt\/gfl395","article-title":"Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders","volume":"21","author":"Galassi","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312490806300_gfw312-B77","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40620-014-0071-2","article-title":"Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease","volume":"28","author":"Russo","year":"2015","journal-title":"J Nephrol"},{"key":"2025102312490806300_gfw312-B78","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/art.20781","article-title":"Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial","volume":"52","author":"Garg","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025102312490806300_gfw312-B79","first-page":"428","article-title":"The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease","volume":"64","author":"Freemont","year":"2005","journal-title":"Clin Nephrol"},{"key":"2025102312490806300_gfw312-B80","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40620-014-0122-8","article-title":"Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study","volume":"28","author":"Ruggeri","year":"2015","journal-title":"J Nephrol"},{"key":"2025102312490806300_gfw312-B81","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000365746","article-title":"Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in Italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study","volume":"37","author":"Ruggeri","year":"2014","journal-title":"Blood Purif"},{"key":"2025102312490806300_gfw312-B82","doi-asserted-by":"crossref","first-page":"e0133938","DOI":"10.1371\/journal.pone.0133938","article-title":"New conclusions regarding comparison of sevelamer and calcium-based phosphate binders in coronary-artery calcification for dialysis patients: a meta-analysis of randomized controlled trials","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"key":"2025102312490806300_gfw312-B83","doi-asserted-by":"crossref","first-page":"e0156891","DOI":"10.1371\/journal.pone.0156891","article-title":"Comparative effectiveness of phosphate binders in patients with chronic kidney disease: a systematic review and network meta-analysis","volume":"11","author":"Sekercioglu","year":"2016","journal-title":"PLoS One"},{"key":"2025102312490806300_gfw312-B84","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.ki.5002059","article-title":"Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients","volume":"71","author":"Block","year":"2007","journal-title":"Kidney Int"},{"key":"2025102312490806300_gfw312-B85","doi-asserted-by":"crossref","first-page":"c278","DOI":"10.1159\/000127361","article-title":"Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis","volume":"108","author":"Takei","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"2025102312490806300_gfw312-B86","first-page":"MR000033","article-title":"Industry sponsorship and research outcome","volume":"12","author":"Lundh","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025102312490806300_gfw312-B87","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/S0140-6736(13)61165-4","article-title":"The demise of calcium-based phosphate binders","volume":"382","author":"Ortiz","year":"2013","journal-title":"Lancet"},{"key":"2025102312490806300_gfw312-B88","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1053\/j.ajkd.2011.06.022","article-title":"Multi-intervention management of calciphylaxis: a report of 7 cases","volume":"58","author":"Baldwin","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2025102312490806300_gfw312-B89","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.2215\/CJN.00810110","article-title":"Serum phosphate and mortality in patients with chronic kidney disease","volume":"5","author":"Eddington","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312490806300_gfw312-B90","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2025102312490806300_gfw312-B91","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.ajkd.2015.01.009","article-title":"Serum phosphorus and progression of CKD and mortality: a meta-analysis of cohort studies","volume":"66","author":"Da","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2025102312490806300_gfw312-B92","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinte.164.12.1285","article-title":"Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis","volume":"164","author":"Pletcher","year":"2004","journal-title":"Arch Intern Med"},{"key":"2025102312490806300_gfw312-B93","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/01.ASN.0000113243.24155.2F","article-title":"Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes","volume":"15","author":"Stevens","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2025102312490806300_gfw312-B94","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2025102312490806300_gfw312-B95","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.ki.5002667","article-title":"Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. No good evidence to promote a general use of sevelamer","volume":"73","author":"Nguyen","year":"2008","journal-title":"Kidney Int"},{"key":"2025102312490806300_gfw312-B96","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1038\/ki.2008.544","article-title":"Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data","volume":"111","author":"Frazao","year":"2008","journal-title":"Kidney Int Suppl"},{"issue":"(Suppl 113)","key":"2025102312490806300_gfw312-B97","first-page":"S22","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD\u2013MBD)","volume":"76","year":"2009","journal-title":"Kidney Int"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/1\/111\/17109583\/gfw312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/1\/111\/17109583\/gfw312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:49:55Z","timestamp":1761238195000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/32\/1\/111\/2931160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,20]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,20]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfw312","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726762538.793524620","asserted-by":"object"}]},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,1]]},"published":{"date-parts":[[2016,9,20]]}}}